EBT Medical, Inc.

EBT Medical, Inc. develops advanced neuromodulation technologies to treat pelvic health disorders, particularly focusing on overactive bladder conditions through innovative, non-invasive solutions. Founded in 2014, EBT Medical, Inc. is based in Toronto, Canada, and specializes in developing neuromodulation technologies for pelvic health treatment.

The company’s core product, NiNA, is currently in development, utilizing the Saphenous nerve’s role in pelvic health. The company raised USD 10 mn in Series A funding in November 2019, co-led by Genesys Capital Management and SV Health Investors, which completed its total fundraising to USD 10 mn. The founder, Paul Yoo, has a history of entrepreneurship, although specific past ventures are not disclosed. EBT Medical's primary focus is on developing innovative neuromodulation technologies aimed at treating pelvic health disorders, emphasizing overactive bladder conditions.

Their core product, NiNA, is under development, designed to modulate pelvic health functions through the Saphenous nerve, providing a drug-free, non-invasive treatment option. The technology aims to be a first-line treatment for patients with overactive bladder and is targeted at healthcare providers, urologists, and specialists in North America and other global markets. EBT Medical's revenue model is based on direct sales of its medical devices to healthcare providers and institutions focused on pelvic health treatment. This structure involves partnerships with urology clinics and hospitals, where devices are procured for clinical use, often accompanied by service agreements for ongoing support.

The pricing strategy for the NiNA device aligns with its advanced neuromodulation technology as the company seeks market authorization, complemented by marketing efforts to promote adoption within the healthcare community. EBT Medical plans to leverage its recent funding of USD 10 mn from November 2019 to support the continued development of its core product, NiNA, and expedite its market authorization process. The company is targeting expansion into North America and potentially other global markets where pelvic health issues are prevalent, aiming for a broader reach by the end of 2023. The funding will be instrumental in advancing product development as well as enhanced marketing efforts to establish a foothold in the healthcare sector.